ArticleiScience2019
Charge Regulation of Self-Assembled Tubules by Protonation for Efficiently Selective and Controlled Drug Delivery.
Article in iScience, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 13 citations in OpenAlex.
- Triethylamine-mediated protonation-deprotonation unlocks dual-drug self assembly to suppress breast cancer progression and metastasis.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Designing supramolecular self-assembly nanomaterials as stimuli-responsive drug delivery platforms for cancer therapy.iScience · 2023Review
- Design, synthesis and applications of responsive macrocycles.Communications chemistry · 2020Review
- Sandwich-structure hydrogels implement on-demand release of multiple therapeutic drugs for infected wounds.RSC advances · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the success for targeted delivery in the body, the efficient release without side effects caused by residual drug remains a challenge. For reducing residual drug, the pH-responsive carriers were prepared by self-assembly from aromatic macrocycles, which were non-toxic and biocompatible. The inner surroundings of aromatic macrocycles could be protonated positively by acid inducing the separation of neighboring macrocycles. Thus, Dox-loaded carriers successfully inhibited the proliferation of carcinoma cells (HepG2 and 4T1) rather than normal cells (HL7702). The effects were further proved in vivo without systemic cytotoxicity. Notably, the responsive environment for drug release depended on the concentration of carriers. Particularly, drug release was promoted by carrier separation. Carrier 2 exhibited preferable anticancer efficacy than carrier 1 due to the efficient release of Dox by full separation of the carrier. Collectively, we have developed a novel strategy serving as a selective and controlled drug release platform for cancer therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.